Xuzhou Central hospital

Xuzhou 221018

8 studies enrolling now · 13 studies all time

What they study most

Acute Respiratory Failure, Advanced Lung Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Alzheimer Disease, Alzheimer's Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Atrial Fibrillation, Chemotherapeutic Toxicity, Colorectal Cancer Metastatic, Elevated Lp(a), Gastric Cancer

Studies at this site

• Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer — Recruiting now
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) — Recruiting now
• A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) — Recruiting now
• A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer — Recruiting now
• A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors — Recruiting now
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Recruiting now
• An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors — Recruiting now
• A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer — Recruiting now
• A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) — Running, not enrolling
• Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) — Running, not enrolling
• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): — Stopped early
• GLORIA-AF Registry Program - Second and Third Phases — Completed
• Third International Study on Mechanical Ventilation — Completed